Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors.

BACKGROUND: Angiogenesis is critical for tumor growth and metastasis. Dual inhibition of VEGF and PDGFR suppresses angiogenesis. This expansion cohort of a phase I study targeted angiogenesis with sorafenib, bevacizumab and low-dose cyclophosphamide in children and young adults with recurrent solid...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Cancer
Autors principals: Federico, Sara M., Caldwell, Kenneth J., McCarville, Mary B., Daryani, Vinay M., Stewart, Clinton F., Mao, Shenghua, Wu, Jianrong, Davidoff, Andrew M., Santana, Victor M., Furman, Wayne L., Pappo, Alberto S., Navid, Fariba
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958650/
https://ncbi.nlm.nih.gov/pubmed/32325418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2020.03.010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars